ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Employees - 685, CEO - Mr. Adam S. Grossman, Sector - Healthcare, Country - US, Market Cap - 4.88B

Altman ZScore(max is 10): 23.43, Piotroski Score(max is 10): 7, Working Capital: $298316000, Total Assets: $510569000, Retained Earnings: $-281679000, EBIT: 152355000, Total Liabilities: $137150000, Revenue: $459381000

- Current Price $20.44 - Analyst Target Price $32.33